Low-dose azathioprine is effective in maintaining remission among Chinese patients with Crohn’s disease

Journal of Translational Medicine

Shudong Xiao³  Xuhang Li⁴  Xueqing Yang¹  Chuanhua Yang³  Yan Gao²  Jianghong Wu³ 

[1] Division of 2008 undergraduate, Anhui Medical University, Hefei, China;Division of Gastroenterology and Hepatology, Tengzhou Central People’s Hospital, Tengzhou, China;Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease; Key Laboratory of Gastroenterology & Hepatology, Ministry of Health (Shanghai Jiao-Tong University), Shanghai, China;Department of Medicine GI Division, Johns Hopkins University School of Medicine, Baltimore, USA

关键词: Chinese patients;    Crohn’s disease;    Maintain remission;    1.0 mg/kg azathiopurine;    <;   

Others  :  826265
DOI  :  10.1186/1479-5876-11-235

 received in 2013-05-24, accepted in 2013-09-24,  发布年份 2013

【 摘 要 】

Background

Azathiopurine (AZA) is efficacious for maintenance remission of Crohn’s disease (CD) at the standard dose of 2.0-2.5 mg/kg for Caucasian. It has been reported that the lower dose (1.0-2.0 mg/kg) in some Asian countries was as effective as the standard dose. In the present study we analyzed the efficacy of <1.0 mg/kg AZA in maintaining remission for Chinese patients.

Methods

The clinical data of all CD patients were reviewed from 1993 to December 2012. The patients who initiated AZA treatment and were followed for ≥ 2 years with complete medical data were included. We divided the patients into two groups according to their initial dose: <1.0 mg/kg group and 1.0-2.0 mg/kg group.

Results

Among 77 patients, 39 (50.6%) started treatment with <1.0 mg/kg AZA and 38 (49.4%) with 1.0-2.0 mg/kg. The mean dose of <1.0 mg/kg group remained under 1.0 mg/kg at 6, 12 and 24 months, even if the doses were adjusted according to efficacy and tolerance. The remission rate in patients of <1.0 mg/kg group was significantly higher than that in those of 1.0-2.0 mg/kg group (P = 0.025). A dose of <1.0 mg/kg AZA was more commonly associated with male gender, older age, heavier body weight and L1 location. Adverse events were observed in 21 of 77 patients (27.3%) and no significant difference in occurrence of adverse events or leucopenia between two groups.

Conclusions

<1.0 mg/kg AZA was effective as 1.0-2.0 mg/kg in maintaining remission among Chinese patients with CD.

【 授权许可】

   
2013 Wu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S, IBD section of the British society of gastroenterology: Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607.
• [2]Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M: Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009., 21CD000067
• [3]D’Haens G, Geboes K, Rutgeerts P: Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc 1999, 50:667-671.
• [4]D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P: Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 1997, 112:1475-1481.
• [5]Rogler G, Bernstein CN, Sood A, Goh KL, Yamamoto-Furusho JK, Abbas Z, Fried M: Role of biological therapy for inflammatory bowel disease in developing countries. Gut 2012, 61:706-712.
• [6]Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, Beaugerie L, Cosnes J: Long-term outcome of patients with Crohn’s disease Who respond to azathioprine. Clin Gastroenterol Hepatol 2013, 11:389-394.
• [7]Lewis JD, Schwartz JS, Lichtenstein GR: Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118:1018-1024.
• [8]Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D’Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O’Morain C, Oresland T, Windsor A, Stange EF, Travis SP, European Crohn’s and Colitis Organisation (ECCO): The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010, 4:28-62.
• [9]Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, Singleton JW: National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology 1979, 77:847-869.
• [10]Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T, Guidelines Project Group of the Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour and Welfare of Japan and the Guidelines Committee of the Japanese Society of Gastroenterology: Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol 2013, 48:31-72.
• [11]Rayner CK, Hart AL, Hayward CM, Emmanuel AV, Kamm MA: Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20:65-71.
• [12]Wang YF, Zhang H, Ouyang Q: Clinical manifestations of inflammatory bowel disease: east and west differences. J Dig Dis 2007, 8:121-127.
• [13]Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6.
• [14]Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
• [15]Kim DU, Kim YH, Kim BJ, Chang DK, Son HJ, Rhee PL, Kim JJ, Rhee JC: The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease. Hepatogastroenterology 2009, 56:1395-1402.
• [16]Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T: Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003, 38:740-746.
• [17]Yang CH, Ding J, Gao Y, Chen X, Yang ZB, Xiao SD: Risk factors that predict the requirement of aggressive therapy among Chinese patients with Crohn’s disease. J Dig Dis 2011, 12:99-104.
• [18]Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y: Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther 2002, 16:79-85.
• [19]Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489.
• [20]Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, Modigliani R, Rambaud JC: Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 27:215-219.
• [21]Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J: Predictors of Crohn’s disease. Gastroenterology 2006, 130:650-656.
• [22]Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR: Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005, 37:282-297.
• [23]Yip JS, Woodward M, Abreu MT, Sparrow MP: How are azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008, 14:514-518.
• [24]APDW2004 Chinese IBD Working Group: Retrospective analysis of 515 cases of Crohn’s disease hospitalization in China: nationwide study from 1990 to 2003. J Gastroenterol Hepatol 2006, 21:1009-1015.
• [25]Zheng JJ, Chu XQ, Shi XH, Zhou CL, Seng BW: Efficacy and safety of azathioprine maintenance therapy in a group of Crohn’s disease patients in China. J Dig Dis 2008, 9:84-88.
• [26]Thia KT, Li M, Ling KL, Kong SC, Ooi CJ: Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients. Inflamm Bowel Dis 2011, 17:809-815.